U.S. Specialized REITs Stock News

NYSE:ONON
NYSE:ONONLuxury

On Holding (ONON) Stock Looks Reasonable After A 42% Fall

On Holding has seen a sharp reset in its share price this year, and the size of that pullback puts a fresh spotlight on whether the current valuation can still be explained by its earnings power. With the stock now trading around US$27.26, the key issue is how that price lines up against what the business is actually generating in profit. The share price is down about 41.9% year to date, which puts pressure on the idea that the current market value reflects what the underlying earnings can...
NYSE:FDX
NYSE:FDXLogistics

FedEx (FDX) Launches Authenticated Delivery, Is The Stock A Bargain?

FedEx (FDX) just rolled out FedEx Authenticated Delivery, a QR code based service aimed at tighter control over high value and sensitive parcels in the U.S. and Canada, giving investors a fresh product move to assess. FedEx shares have softened recently, with the 30 day share price return down 6.6% and the 90 day return down 7.6%, yet the 1 year total shareholder return of 65.5% and 5 year total shareholder return of 83.9% point to strong longer term momentum as the company rolls out new...
NasdaqCM:PGY
NasdaqCM:PGYSoftware

Pagaya Technologies (PGY) Adds Fintech Veteran Jason Gardner To Its Board

Pagaya Technologies (NasdaqCM:PGY) appointed Marqeta founder Jason Gardner to its Board of Directors. Gardner brings more than 20 years of fintech and payments experience, including leading Marqeta through its IPO. His board role aligns with Pagaya's focus on AI-driven lending marketplace products and payment technology. The Jason Gardner board appointment is important, but investors should weigh it alongside other Pagaya developments. Our analysis turns up 2 warning signs for Pagaya...
NYSE:DLR
NYSE:DLRSpecialized REITs

Why Digital Realty Trust (DLR) Is Back In The Spotlight

Digital Realty Trust (DLR) has been drawing fresh attention after a run of AI focused moves, including a new AXG partnership, the rollout of ServiceFabric MCP, a joint venture in Türkiye, and an expanded Nairobi campus. Recent trading tells a mixed story for Digital Realty Trust. The share price has eased over the past week and quarter, with the 7 day share price return down 3.43% and the 90 day share price return down 6.86%. However, the year to date share price return of 17.47% and 3 year...
NasdaqGS:MGEE
NasdaqGS:MGEEElectric Utilities

MGE Energy (MGEE) Stock Looks Above Fair Value On Dividends

MGE Energy has seen a mixed share price record in recent years, with the stock pulling back over the past 12 months after earlier gains. That leaves investors weighing whether the current price around US$74 is adequately supported by the utility's future stream of dividend payments. Over the past 5 years, MGE Energy has delivered a total return of 9.9%, which puts real weight on the question of how much of that experience can reasonably be tied to its dividend profile. The group runs a...
NasdaqGS:LIN
NasdaqGS:LINChemicals

Linde (LIN), What Is Drawing Fresh Attention Now?

Linde (LIN) grabbed investor attention after its latest share price move, with the industrial gas specialist now trading around $460.40 per share on the Nasdaq. Short term performance has been mixed. Recent trading has been choppy for Linde, with the 30 day share price return down 5.57% and the 90 day share price return lower by 10.90%, even though the year to date share price return is still up 7.29%. That pullback contrasts with a 1 year total shareholder return that is slightly negative at...
NasdaqGS:ALNY
NasdaqGS:ALNYBiotechs

Will RNAi Market Growth Change Alnylam Stock's Narrative?

Recent market research points to significant projected expansion in global RNA interference therapeutics, with Alnylam Pharmaceuticals identified as a leading participant in RNA-based treatments for hard-to-treat conditions, including hereditary transthyretin-mediated amyloidosis. The emphasis on rare disease prevalence and precision medicine investment highlights how Alnylam Pharmaceuticals's focus on hATTR and RNAi platforms ties directly into an expanding treatment universe and potential...
NasdaqGM:FCEL
NasdaqGM:FCELElectrical

Is FuelCell Energy (FCEL) A Bargain As Ratepayer Protection Act Fuels Data Center Hopes?

The latest move in FuelCell Energy (FCEL) has been sparked by legislation, not earnings. The U.S. House passed the Ratepayer Protection Act, which shifts grid upgrade costs for heavy power users such as large data centers. For context, FuelCell Energy’s recent move comes after a sharp year-to-date share price return of 121.66% and a 1-year total shareholder return of 116.63%. However, momentum has faded in recent months, with a 30-day share price return down 7.32% and a 90-day share price...
NYSE:BNY
NYSE:BNYCapital Markets

What Does Bank Of New York Mellon Corporation (BNY) Losing An ADR Mandate Mean?

BNY (NYSE:BNY) has lost its role as depositary bank for Kazia Therapeutics' American Depositary Receipt program. Kazia Therapeutics has appointed JPMorgan Chase as the new depositary for its ADR program, replacing Bank of New York Mellon Corporation. The ADR depositary switch highlights competitive pressure on BNY's global custody and asset servicing franchise. The move by Kazia Therapeutics to shift its ADR depositary from BNY to JPMorgan Chase tells only part of the story. Take a look at 1...
NYSE:NVO
NYSE:NVOPharmaceuticals

Novo Nordisk (NVO) Secures Key EU Panel Backing For Child Growth Drug

Novo Nordisk (NYSE:NVO) received a positive opinion from the European Medicines Agency's CHMP for Sogroya as a treatment for idiopathic short stature in children. If approved by the European Commission, Sogroya could become the first authorised therapy for idiopathic short stature in the EU pediatric population. The opinion supports Novo Nordisk's effort to expand its rare disease and pediatric endocrinology portfolio beyond existing growth hormone deficiency indications. The CHMP backing...
NasdaqCM:PLSE
NasdaqCM:PLSEMedical Equipment

What Could Pulse Biosciences (PLSE) 100 Patient Study Milestone Mean?

Pulse Biosciences (NasdaqCM: PLSE) reported completion of 100 patient enrollment in its PRECISE-BTN thyroid nodule study using the nPulse Vybrance Percutaneous Electrode System. The PRECISE-BTN trial expanded from an original 50 patients to 100 patients across multiple participating centers. Management plans future disclosure of clinical data from PRECISE-BTN, which is intended to support potential regulatory clearance for nPulse Vybrance. The completed PRECISE-BTN enrollment matters, but it...
NasdaqGS:TTMI
NasdaqGS:TTMIElectronic

TTM Technologies (TTMI) Stock Could Be 11% Overvalued As Third Point Buys In

TTM Technologies has delivered very large gains over the past five years, which puts a sharp focus on whether the current US$117.97 share price lines up with the cash flows that support the business. With an intrinsic value estimate based on a Discounted Cash Flow (DCF) model available, the key issue is how that cash flow view compares with a stock that has already rewarded early holders in a big way. Over 5 years, the stock is up about 8x. Anyone looking at TTM Technologies today has to ask...
NYSE:DHT
NYSE:DHTOil and Gas

Should Long Term Charter Deal Require Action From DHT Holdings (DHT) Investors?

DHT Holdings announced a three year time charter for the 2016 built VLCC DHT Panther at a rate of $100,000 per day with a global energy company, with the contract starting in October 2026. The fixed multi year charter on a modern VLCC locks in contracted revenue for DHT Holdings and provides greater visibility on fleet utilization compared with relying purely on spot exposure. We will look at how DHT Holdings' investment narrative around cash flow stability is affected by the $100,000 daily...
NasdaqGS:TROW
NasdaqGS:TROWCapital Markets

How Three New ETFs At T. Rowe Price Group (TROW) Have Changed Its Investment Story

T. Rowe Price Group recently launched three fully transparent actively managed equity ETFs on the NASDAQ, targeting biotech, U.S. small caps, and U.S. mid caps, with expense ratios between 0.47% and 0.59%. The new ETFs broaden T. Rowe Price Group’s active ETF shelf across key equity segments, which may support more diversified fee streams and help address competitive pressure from lower cost passive products. We will look at how T. Rowe Price Group’s investment narrative intersects with this...
NYSE:AMC
NYSE:AMCEntertainment

AMC Entertainment Holdings (AMC) Could Be 6% Undervalued As Premium Formats Lift Attendance

Recent commentary on AMC Entertainment Holdings (AMC) points to a stronger film slate and higher demand for premium formats. This is lifting attendance and sentiment even as investors continue to watch the company’s leverage closely. At a share price of US$2.70, AMC Entertainment Holdings has seen a 7 day share price return of 9.76% and a year to date share price return of 67.70%, yet the 1 year total shareholder return has declined 10.30%, signalling that recent momentum contrasts with a...
NYSE:PFE
NYSE:PFEPharmaceuticals

Will Conference Outlook Change Pfizer (PFE) Stock Narrative

Pfizer recently presented at the Morgan Stanley 24th Annual Global Healthcare Conference in New York, with CEO Albert Bourla outlining how the business is handling debt, patent expiries, and future product opportunities. The discussion put a spotlight on how Pfizer balances a large dividend outlay and more than US$60b of acquisition driven debt with the need to fund its oncology, obesity, and vaccine pipelines. We will now look at how Pfizer's investment narrative could be affected by CEO...
NasdaqGS:TCOM
NasdaqGS:TCOMHospitality

Trip.com Group (TCOM) Puts AI Into Business Travel With Agent ONE

Trip.com Group (NasdaqGS: TCOM) has introduced Agent ONE, an AI-powered suite under its Trip.Biz unit for corporate travel management. Agent ONE is designed to shorten booking times for employees and give travel managers centralized oversight of business trips and compliance. The launch signals a push by Trip.com Group to expand beyond leisure customers into global corporate travel using artificial intelligence tools. The Agent ONE rollout within Trip.Biz comes alongside broader shifts our...
NasdaqGS:UPST
NasdaqGS:UPSTConsumer Finance

Is Upstart Holdings (UPST) Trading At A Premium Or About Right?

Upstart Holdings has seen its share price come under heavy pressure in recent years, and that slide puts a spotlight on a simple question for you as an investor. Is the current valuation of Upstart stock still supported by what the business is earning today and what those earnings suggest it could deliver over time. Over the past 5 years, the share price has fallen about 92.4%, which puts a lot of weight on whether the remaining market value lines up with the company’s earnings power. The...
NYSE:UVV
NYSE:UVVTobacco

Universal (UVV) Could Be 34% Undervalued As Leadership Changes Raise Fresh Questions

Universal (UVV) drew fresh attention after terminating J. Patrick O’Keefe, Vice President of Ingredients, without cause on September 15, 2026, while continuing its previously announced search for his successor. Universal’s share price has eased in recent months, with the stock down 14.3% over 90 days and 16.1% year to date at US$44.14. Longer term total shareholder returns of 11.2% over three years and 25.9% over five years point to a more resilient history despite recent weakness. Capitalize...
NYSE:WPC
NYSE:WPCREITs

W. P. Carey (WPC) Stock Looks Undervalued On Its 40% Three Year Run

W. P. Carey has delivered solid long term gains for holders, even as more recent trading has been choppy. That puts a spotlight on whether the earnings behind the stock now justify the current price. With real estate investors also watching fresh company updates, the question is how much of the underlying profit story is already reflected in that US$66.26 closing level. Over the past 3 years the stock has returned 40.2%, which raises the stakes on whether the current earnings profile can...
NYSE:BRK.A
NYSE:BRK.ADiversified Financial

Why Berkshire Hathaway (BRK.A) Is Getting Attention Now

Berkshire Hathaway (BRK.A) moved back into the spotlight after Warren Buffett stepped down as chairman and became Chairman Emeritus, with long-time director Howard Buffett taking over the board role. Recent boardroom headlines have arrived while Berkshire Hathaway’s 1 month share price return of 2.70% and 3 month share price return of 3.98% point to steady, if measured, momentum, with a 1 year total shareholder return of 3.13% and a 5 year total shareholder return of 82.64% reminding...
NasdaqGS:MAT
NasdaqGS:MATLeisure

How Investors Are Reacting To Mattel (MAT) New Shows And Licensing Deal

Mattel announced a new Thomas & Friends animated special, Really Helpful Engines, along with a refreshed Railway Stories series and reimagined global toy line, plus a separate multi-year licensing deal bringing Bluey into Barbie, Hot Wheels, Fisher-Price, Polly Pocket and UNO products. The twin push into fresh Thomas content tied directly to a redesigned Easy Connect track system and a broad Bluey licensing rollout deepens Mattel’s use of owned and partner IP across both streaming and...
NYSE:APAM
NYSE:APAMCapital Markets

What Artisan Partners Asset Management AUM Decline Means For Shareholders

Artisan Partners Asset Management has faced pressure from sluggish 2.8% annualized revenue growth, a 1.3% annual decline in EPS, and a recent month-on-month drop in assets under management. The combination of softer long term fundamentals and fresh AUM weakness points to business headwinds that go beyond short term market noise. The focus now turns to how this weaker earnings and assets under management profile could reshape Artisan Partners Asset Management's investment narrative. Balance...
NasdaqGS:MZTI
NasdaqGS:MZTIFood

Marzetti (MZTI) Slides On Slower Growth, Is The Valuation Now Too Low?

Marzetti (MZTI) came back into focus after fresh commentary highlighted its slower annual revenue expansion versus other consumer staples peers and a forward P/E of 15.3x. This has prompted investors to reassess what they are paying for this business. Marzetti’s recent share price slide, with a 30 day share price return down 10.49% and year to date share price return down 39.28%, points to fading momentum as investors weigh slower revenue expansion against that 15.3x forward P/E. The 1 year...